JP2024542610A5 - - Google Patents

Info

Publication number
JP2024542610A5
JP2024542610A5 JP2024531580A JP2024531580A JP2024542610A5 JP 2024542610 A5 JP2024542610 A5 JP 2024542610A5 JP 2024531580 A JP2024531580 A JP 2024531580A JP 2024531580 A JP2024531580 A JP 2024531580A JP 2024542610 A5 JP2024542610 A5 JP 2024542610A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
ring
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542610A (ja
Filing date
Publication date
Priority claimed from GBGB2117127.7A external-priority patent/GB202117127D0/en
Application filed filed Critical
Publication of JP2024542610A publication Critical patent/JP2024542610A/ja
Publication of JP2024542610A5 publication Critical patent/JP2024542610A5/ja
Pending legal-status Critical Current

Links

JP2024531580A 2021-11-26 2022-11-25 神経学的状態の治療のためのスルホンアミド化合物 Pending JP2024542610A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2117127.7A GB202117127D0 (en) 2021-11-26 2021-11-26 Compounds
GB2117127.7 2021-11-26
PCT/GB2022/053000 WO2023094830A1 (en) 2021-11-26 2022-11-25 Sulfonamide compounds for the treatment of neurological conditions

Publications (2)

Publication Number Publication Date
JP2024542610A JP2024542610A (ja) 2024-11-15
JP2024542610A5 true JP2024542610A5 (cg-RX-API-DMAC7.html) 2025-11-19

Family

ID=80038556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531580A Pending JP2024542610A (ja) 2021-11-26 2022-11-25 神経学的状態の治療のためのスルホンアミド化合物

Country Status (11)

Country Link
US (1) US20250115569A1 (cg-RX-API-DMAC7.html)
EP (1) EP4436955A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542610A (cg-RX-API-DMAC7.html)
KR (1) KR20240111787A (cg-RX-API-DMAC7.html)
CN (1) CN118317950A (cg-RX-API-DMAC7.html)
AU (1) AU2022396783A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237721A1 (cg-RX-API-DMAC7.html)
GB (1) GB202117127D0 (cg-RX-API-DMAC7.html)
IL (1) IL312851A (cg-RX-API-DMAC7.html)
MX (1) MX2024006436A (cg-RX-API-DMAC7.html)
WO (1) WO2023094830A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202308160D0 (en) * 2023-05-31 2023-07-12 Lario Therapeutics Ltd Compounds
GB202308164D0 (en) * 2023-05-31 2023-07-12 Lario Therapeutics Ltd Compounds
GB202308165D0 (en) * 2023-05-31 2023-07-12 Lario Therapeutics Ltd Compounds
WO2025158150A1 (en) * 2024-01-24 2025-07-31 Lario Therapeutics Limited Heterocyclic compounds as modulators of cav2.3
IT202400001329A1 (it) * 2024-01-24 2025-07-24 Lario Therapeutics Ltd Composti.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500783A (ja) * 2008-08-22 2012-01-12 エヴォテック・アクチエンゲゼルシャフト 新しいブラジキニンb1拮抗薬
US20130190356A1 (en) * 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
CA3122383A1 (en) * 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
EP2998294A1 (en) * 2014-09-16 2016-03-23 Sanofi Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP3638283B1 (en) 2017-06-14 2024-07-17 Lario Therapeutics Ltd. Antagonists of cav2.3 r-type calcium channels for the treatment of neurodegenerative diseases
JP2021017447A (ja) * 2019-07-18 2021-02-15 ロート製薬株式会社 外用組成物

Similar Documents

Publication Publication Date Title
JP2017531020A5 (cg-RX-API-DMAC7.html)
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
JP2020519606A5 (cg-RX-API-DMAC7.html)
MX2010006182A (es) Derivados de isoxazolo-piridazina.
JP2021522206A5 (cg-RX-API-DMAC7.html)
JP2020514317A5 (cg-RX-API-DMAC7.html)
JP2020521740A5 (cg-RX-API-DMAC7.html)
JP2013010792A5 (cg-RX-API-DMAC7.html)
JP2018505898A5 (cg-RX-API-DMAC7.html)
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
JP2012524053A5 (cg-RX-API-DMAC7.html)
JP2017523169A5 (cg-RX-API-DMAC7.html)
JP2020514318A5 (cg-RX-API-DMAC7.html)
IL275562B1 (en) Compositions and methods for treating cns disorders
JP2017052786A5 (cg-RX-API-DMAC7.html)
JP2022550459A5 (cg-RX-API-DMAC7.html)
JP2013512903A5 (cg-RX-API-DMAC7.html)
JP2010510999A5 (cg-RX-API-DMAC7.html)
CA2491895A1 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2012503655A5 (cg-RX-API-DMAC7.html)
JP2015516429A5 (cg-RX-API-DMAC7.html)
MX2010005753A (es) Derivados de isoxazolo-pirazina.
JP2008517923A5 (cg-RX-API-DMAC7.html)
JP2017525699A5 (cg-RX-API-DMAC7.html)
JP2017533930A5 (cg-RX-API-DMAC7.html)